Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: Nested case-control study

Pharmacotherapy

Volumn 25, Issue 10 I, 2005, Pages 1296-1302

  Graumlich, James F ^a   Habis, Saba ^b   Avelino, Rosario R ^b   Salverson, Sandra M ^b   Gaddamanugu, Madhavi ^b   Jamma, Kiranmai ^b,c   Aldag, Jean C ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b OSF SAINT FRANCIS MEDICAL CENTER   (United States)

^c Christie Clinic   (United States)

Author keywords

Blood glucose; Fluoroquinolones; Hypoglycemia; Risk assessment

Indexed keywords

GATIFLOXACIN; GLUCOSE; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SEPSIS; TEACHING HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; FEMALE; FLUOROQUINOLONES; HUMANS; HYPOGLYCEMIA; MALE; MIDDLE AGED; OFLOXACIN; RISK FACTORS;

EID: 26044471430     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.10.1296     Document Type: Article

References (26)

1. Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging 2003;20:289-302.
2. Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH. Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Am J Med 2002;113:232-4.
3. Baker SE, Hangii MC. Possible gatifloxacin-induced hypoglycemia. Ann Pharmacother 2002;36:1722-6.
4. Biggs WS. Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients. J Am Board Fam Pract 2003;16:455-7.
5. LeBlanc M, Belanger C, Cossette P. Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy. Pharmacotherapy 2004;24:926-31.
6. Friedrich LV, Dougherty R. Fatal hypoglycemia associated with levofloxacin. Pharmacotherapy 2004;24:1807-12.
7. Roberge RJ, Kaplan R, Frank R, Fore C. Glyburide-ciprofloxacin interaction with resistant hypoglycemia. Ann Emerg Med 2000;36:160-3.
8. Lin G, Hays DP, Spillane L. Refractory hypoglycemia from ciprofloxacin and glyburide interaction. J Toxicol Clin Toxicol 2004;42:295-7.
9. Gajjar DA, LaCreta FP, Kollia GD, et al. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy 2000;20(6 suppl 2):76S-86.
10. Coblio NA, Mowrey K, McCright P, Means H, McCormick MT. Use of a data warehouse to examine the effect of fluoroquinolones on glucose metabolism. Am J Health-Syst Pharm 2004;61:2545-8.
11. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997;278:40-3.
12. van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735-41.
13. Tabachnick BG, Fiddel LS, ed. Using multivariate statistics, 4th ed. Boston: Allyn and Bacon, 2001.
14. Shilo S, Berezovsky S, Friedlander Y, Sonnenblick M. Hypoglycemia in hospitalized nondiabetic older patients. J Am Geriatr Soc 1998;46:978-82.
15. Kagansky N, Levy S, Rimon E, et al. Hypoglycemia as a predictor of mortality in hospitalized elderly patients. Arch Intern Med 2003;163:1825-9.
16. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112.
17. Petri WA. Antimicrobial agents: sulfonamides, trimethoprim- sulfamethoxazole, quinolones, and agents for urinary tract infections. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 10th ed. New York: McGraw Hill, 2001:1181-3.
18. Maeda N, Tamagawa T, Niki I, et al. Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Br J Pharmacol 1996;117:372-6.
19. Zûnkler BJ, Wos M. Effects of lomefloxacin and norfloxacin on pancreatic beta-cell ATP-sensitive K(+) channels. Life Sci 2003;73:429-35.
20. Gavin JR III, Kubin R, Choudhri S, et al. Moxifloxacin and glucose homeostasis: a pooled analysis of the evidence from clinical and postmarketing studies. Drug Saf 2004;27:671-86.
21. Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial 2000;13:4-8.
22. Yerkovich ST, Rigby PJ, Fournier PA, Olynyk JK, Yeoh GC. Kupffer cell cytokines interleukin-1β and interleukin-10 combine to inhibit phosphoenolpyruvate carboxykinase and gluconeogenesis in cultured hepatocytes. Int J Biochem Cell Biol 2004;36:1462-72.
23. Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001;161:1653-9.
24. Mandell LA. Safety and efficacy of gatifloxacin in community-acquired pneumonia: rationale for the Tequin clinical experience study (TeqCES). Diagn Microbiol Infect Dis 2002;44:65-7.
25. Letourneau G, Morrison H, McMorran M. Gatifloxacin (Tequin): hypoglycemia and hyperglycemia. Available from http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/ adrv13n3_e.html#1. Accessed March 22, 2005.
26. Queale WS, Seidler AJ, Brancati FL. Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus. Arch Intern Med 1997;157:545-52.